Form 10-K INSMED Inc For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
UBS Starts Insmed (INSM) at Buy, 'We see ~60% upside to the current share price'
February 26, 2024 4:22 PM ESTUBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ: INSM) with a Buy rating and a price target of $46.00.
The analyst comments "We are initiating on INSM with a Buy rating and $46 PT. INSM is a commercial-stage biotech developing therapies for pulmonary... More
